Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Glioblastoma 2Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Healthy Volunteer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 15Nivolumab 10Ipilimumab 7cemiplimab 6dabrafenib 4binimetinib 4Dacarbazine 4trametinib 3encorafenib 3Drug Therapy 3Allovectin-7 3zanolimumab 2talabostat 2lifileucel 2aldesleukin 2Vemurafenib 2Tablets 2Semaxinib 2Intravital Microscopy 2Interleukin-2 2Fluorouracil 2vitespin 1veliparib 1varlilumab 1tozuleristide 1tin etiopurpurin 1tilsotolimod 1spartalizumab 1sotigalimab 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Skin Neoplasms × poly ICLC × Clear all
NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

BioNTech SE

Phase 1 Completed
34 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡